Martin Johansson
Director Ejecutivo en Glactone Pharma AB .
Perfil
Martin Johansson is the founder of Glactone Pharma AB, which he founded in 2012 and where he holds the title of Chief Executive Officer.
He is currently an Associate Professor at the University of Lund.
Previously, he worked at Respiratorius AB from 2006 to 2011 as a Manager-Chemistry.
Cargos activos de Martin Johansson
| Empresas | Cargo | Inicio |
|---|---|---|
| University of Lund | Corporate Officer/Principal | - |
Glactone Pharma AB
 Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Director Ejecutivo | 01/01/2012 |
Antiguos cargos conocidos de Martin Johansson.
| Empresas | Cargo | Fin |
|---|---|---|
Respiratorius AB
 Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Director Técnico/Científico/I+D | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
 | Health Technology |
| Empresas privadas | 1 |
|---|---|
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Martin Johansson
